Saredutant

Saredutant, or SR 48968, is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by sanofi-aventis. Its mechanism of action is different from antidepressants currently available on the market. It works by blocking the effects of Neurokinin A at the NK-2 receptor.

Phase III studies are currently being conducted.